A group of senators has urged the US Federal Trade Commission to closely scrutinise mergers in the pharmaceutical industry, which it said “increase competition issues and stifle innovation”.
A US judge dismissed antitrust counterclaims brought against Allergan and Duke University earlier this week, in a lawsuit the pair filed against generics maker Akorn.
This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.
The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz.
The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
A Takeda subsidiary cannot overturn a $155 million jury verdict that it infringed one of Bayer’s patents, a district court has ruled.
Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.